Treatment of two HNSCC cell lines with the Wnt antagonist sFRP4 resulted in reduced Wnt activity, impaired clonogenicity, decreased expression of stem cell associated markers, and critically increased sensitivity to cisplatin [113]. Here, SFRP4 is linked to head and neck squamous cell carcinoma.